Literature DB >> 22302659

The Role of Regulatory T Cells in Mesothelioma.

Demelza J Ireland1, Haydn T Kissick2, Manfred W Beilharz3.   

Abstract

Malignant mesothelioma (MM) appears to be responsive to immunotherapy. The lack of complete tumour cure as a result of many immunotherapies tested to date suggests that the immune response to MM is complex and multi-parametric. Regulatory T (Treg) cells are prevalent within murine and human mesotheliomas with their removal shown to result in tumour growth inhibition and the release of anti-tumour effector T cells from immunosuppression. The targeting of immune checkpoints as treatments for various solid tumours has recently shown promise in clinical settings. In addition, synergy between chemotherapy and immunotherapy has been demonstrated for many cancers, including mesothelioma. Here we demonstrate Treg cells as critical mediators of the anti-tumour immune response to MM and potential targets for anti-tumour immunotherapy; though the timing and dosage of Treg cell manipulating immunotherapies need to be optimised.

Entities:  

Keywords:  Cancer; Immunosuppression; Immunotherapy; Malignant mesothelioma; Regulatory T cells

Year:  2012        PMID: 22302659      PMCID: PMC3399069          DOI: 10.1007/s12307-012-0100-4

Source DB:  PubMed          Journal:  Cancer Microenviron        ISSN: 1875-2284


  63 in total

1.  Enrichment of Foxp3+ CD4 regulatory T cells in migrated T cells to IL-6- and IL-8-expressing tumors through predominant induction of CXCR1 by IL-6.

Authors:  Shingo Eikawa; Yoshihiro Ohue; Kenta Kitaoka; Toshiki Aji; Akiko Uenaka; Mikio Oka; Eiichi Nakayama
Journal:  J Immunol       Date:  2010-11-03       Impact factor: 5.422

2.  The contribution of occupational risks to the global burden of disease: summary and next steps.

Authors:  Marilyn Fingerhut; Deborah Imel Nelson; T Driscoll; Marisol Concha-Barrientos; Kyle Steenland; Laura Punnett; Annette Prüss-Ustün; J Leigh; C Corvalan; G Eijkemans; J Takala
Journal:  Med Lav       Date:  2006 Mar-Apr       Impact factor: 1.275

3.  Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms.

Authors:  Zvi G Fridlender; Jing Sun; Sunil Singhal; Veena Kapoor; Guanjun Cheng; Eiji Suzuki; Steven M Albelda
Journal:  Mol Ther       Date:  2010-08-03       Impact factor: 11.454

4.  Inhibition of interleukin-8 reduces human malignant pleural mesothelioma propagation in nude mouse model.

Authors:  G Galffy; K A Mohammed; N Nasreen; M J Ward; V B Antony
Journal:  Oncol Res       Date:  1999       Impact factor: 5.574

Review 5.  Regulatory T cells in tumor immunity.

Authors:  Hiroyoshi Nishikawa; Shimon Sakaguchi
Journal:  Int J Cancer       Date:  2010-08-15       Impact factor: 7.396

6.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

Authors:  Julie R Brahmer; Charles G Drake; Ira Wollner; John D Powderly; Joel Picus; William H Sharfman; Elizabeth Stankevich; Alice Pons; Theresa M Salay; Tracee L McMiller; Marta M Gilson; Changyu Wang; Mark Selby; Janis M Taube; Robert Anders; Lieping Chen; Alan J Korman; Drew M Pardoll; Israel Lowy; Suzanne L Topalian
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

7.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.

Authors:  Jason D Fontenot; Marc A Gavin; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

8.  Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo.

Authors:  Mei-Ling Chen; Mikaël J Pittet; Leonid Gorelik; Richard A Flavell; Ralph Weissleder; Harald von Boehmer; Khashayarsha Khazaie
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-27       Impact factor: 11.205

9.  Competing feedback loops shape IL-2 signaling between helper and regulatory T lymphocytes in cellular microenvironments.

Authors:  Dorothea Busse; Maurus de la Rosa; Kirstin Hobiger; Kevin Thurley; Michael Flossdorf; Alexander Scheffold; Thomas Höfer
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-28       Impact factor: 11.205

10.  Developmental stage, phenotype, and migration distinguish naive- and effector/memory-like CD4+ regulatory T cells.

Authors:  Jochen Huehn; Kerstin Siegmund; Joachim C U Lehmann; Christiane Siewert; Uta Haubold; Markus Feuerer; Gudrun F Debes; Joerg Lauber; Oliver Frey; Grzegorz K Przybylski; Uwe Niesner; Maurus de la Rosa; Christian A Schmidt; Rolf Bräuer; Jan Buer; Alexander Scheffold; Alf Hamann
Journal:  J Exp Med       Date:  2004-02-02       Impact factor: 14.307

View more
  5 in total

1.  Phenotypic and functional analysis of malignant mesothelioma tumor-infiltrating lymphocytes.

Authors:  Astero Klampatsa; Shaun M O'Brien; Jeffrey C Thompson; Abhishek S Rao; Jason E Stadanlick; Marina C Martinez; Maria Liousia; Edward Cantu; Keith Cengel; Edmund K Moon; Sunil Singhal; Evgeniy B Eruslanov; Steven M Albelda
Journal:  Oncoimmunology       Date:  2019-07-13       Impact factor: 8.110

2.  A single centre phase II trial to assess the immunological activity of TroVax® plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma - the SKOPOS trial.

Authors:  Jason F Lester; Angela C Casbard; Saly Al-Taei; Richard Harrop; Lajos Katona; Richard L Attanoos; Zsuzsanna Tabi; Gareth O Griffiths
Journal:  Oncoimmunology       Date:  2018-09-07       Impact factor: 8.110

3.  Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesothelioma.

Authors:  Iris Chiara Salaroglio; Ivana Campia; Joanna Kopecka; Elena Gazzano; Sara Orecchia; Dario Ghigo; Chiara Riganti
Journal:  Oncotarget       Date:  2015-01-20

4.  Human malignant mesothelioma is recapitulated in immunocompetent BALB/c mice injected with murine AB cells.

Authors:  Rosanna Mezzapelle; Eltjona Rrapaj; Elena Gatti; Chiara Ceriotti; Francesco De Marchis; Alessandro Preti; Antonello E Spinelli; Laura Perani; Massimo Venturini; Silvia Valtorta; Rosa Maria Moresco; Lorenza Pecciarini; Claudio Doglioni; Michela Frenquelli; Luca Crippa; Camilla Recordati; Eugenio Scanziani; Hilda de Vries; Anton Berns; Roberta Frapolli; Renzo Boldorini; Maurizio D'Incalci; Marco E Bianchi; Massimo P Crippa
Journal:  Sci Rep       Date:  2016-03-10       Impact factor: 4.379

5.  Low-dose cyclophosphamide depletes circulating naïve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy.

Authors:  Lisanne Noordam; Margaretha E H Kaijen; Koen Bezemer; Robin Cornelissen; Lex A P W M Maat; Henk C Hoogsteden; Joachim G J V Aerts; Rudi W Hendriks; Joost P J J Hegmans; Heleen Vroman
Journal:  Oncoimmunology       Date:  2018-07-30       Impact factor: 8.110

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.